Prana Biosciences is revolutionizing the field of biologic medicine by leveraging cutting-edge AI-driven solutions to develop top-tier monoclonal antibodies as affordable biobetters. These biobetters are enhanced versions of the world’s most successful biologics, designed to improve safety, efficacy, and clinical outcomes for a diverse patient population.
“Biologic medicines have become an essential component of pharmaceutical treatment for complex conditions, and our mission at Prana Biosciences is to make these treatments more accessible and effective for a broader range of patients,” said Dr. Bharat Tewarie, MD, MBA, CEO of Prana Biosciences. “Through our innovative approach, we aim to address the challenges of affordability, accessibility, and efficacy in biologic therapies.”
Biologics are the fastest-growing drug segment in the United States, renowned for their efficacy in treating diseases such as autoimmune disorders, cancer, neurological conditions, and infectious diseases. Despite their benefits, affordability and access remain significant hurdles. Biologics account for 40% of total pharmaceutical spending, yet only 2% of patients use them. By 2025, biologics could reach an additional 1.2 million U.S. patients, promoting equitable access across diverse populations.
The global monoclonal antibodies market, valued at USD 186.6 billion in 2022, is projected to surpass USD 566.72 billion by 2032, growing at a CAGR of 11.8% from 2023 to 2033. However, the current capacity of third-party manufacturers is insufficient to meet the rising demand. Prana Biosciences addresses this gap by planning to build a stepwise antibody production facility, transitioning from a discovery to a GMP biomanufacturing unit capable of serving small and midsize biotech companies.
For biotech companies, the challenge lies in finding third-party manufacturers for biologics due to limited capacity. Prana’s solution is to establish an in-house manufacturing facility with the capacity to support small and midsize biotech companies.
For patients, many biologics are unaffordable or ineffective due to a lack of development for diverse populations. Prana’s biobetters offer improved versions of commercially successful biologics, enhancing their safety and efficacy profiles to benefit a wider range of patients.
For large pharmaceutical companies, whose products lose intellectual property protection over time, Prana’s biobetters provide an improved iteration of originator biologic therapies, extending their lifecycle and maintaining their competitive edge.
Prana Biosciences stands out in the biotech industry by leveraging state-of-the-art antibody design and production technologies, including AI, to discover, develop, and commercialize biobetters of leading monoclonal antibodies for immunology and oncology.
“Our AI-driven solutions enable us to optimize therapeutic efficacy, patient safety, and manufacturability of our antibody candidates,” Dr. Tewarie explained. “This approach not only enhances binding and function but also ensures patient safety by eliminating potential risks.”
Prana’s facilities support the full range of R&D activities, from novel antibody isolation and characterization to biologics manufacturing process development and preclinical toxicology studies. This comprehensive infrastructure enables Prana to meet the growing demand for biologics while maintaining high standards of quality and innovation.
The biotech industry faces significant challenges, including patent cliffs, clinical data issues, soft capital markets, investor apprehension, and layoffs. Prana Biosciences is uniquely positioned to address these challenges by developing biobetters and setting up agile manufacturing operations. This strategy not only supports Prana’s needs but also provides CDMO services to other biotech startups, generating additional revenue and fostering industry growth.
Prana’s leadership team, with deep expertise in developing best-in-class biobetters and regulatory proficiency, is dedicated to broadening its biologics discovery and manufacturing footprint on a global scale. The company’s facility will serve as a nucleus for molecule discovery and development while operating as a CDMO for regional biotech firms.
For more information, please contact Dr. Bharat Tewarie at Bharat.Tewarie@pranabiosciences.com or call 470-363-8980.
Media Contact
Company Name: Prana Biosciences
Contact Person: Bharat Tewarie
Email: Send Email
Country: United States
Website: https://pranabiosciences.com/
